FDA approves new treatment for NSCLC
FDA approves Tepmetko as a once-daily oral MET inhibitor for NSCLC with METex14 skipping alterations
NSCLC
Puma Biotechnology reports interim SUMMIT results for neratinib
Puma Biotechnology has announced interim results from the Phase 2 SUMMIT trial of neratinib
Puma Biotechnology reports interim SUMMIT results for neratinib
LOS ANGELES—Puma Biotechnology Inc. has announced interim results from the ongoing SUMMIT trial of neratinib in the cohort of metastatic non-small cell lung cancer (NSCLC) patients with epidermal growth factor (EGFR) exon 18 mutations that have been previously treated with an EGFR-targeted tyrosine kinase inhibitor (TKI).
